Home / Blog

What Seth Klarman and Baupost Group Bought in Q2 2026

Seth Klarman's Baupost Group reveals new positions in Aon, Visa, and Vaxcyte in its Q2 2026 13F filing. Explore the strategy behind the value-investing legend.

Stock AnalysisFintwit Team·Aug 7, 2026·3 min read
What Seth Klarman and Baupost Group Bought in Q2 2026
Seth Klarman's Baupost Group disclosed 5 new equity positions in its Q2 2026 13F filing, signaling a pivot toward high-quality, cash-generative assets. The firm added 769,000 shares of Aon Plc and 701,355 shares of Visa Inc. to its portfolio.

Why Seth Klarman matters

Seth Klarman founded Baupost Group in 1982 with $27 million in initial capital. Over the past four decades, the firm has grown to manage over $22 billion in assets under management.

Klarman is widely recognized for his patient, risk-averse, and contrarian value-investing philosophy. He prioritizes a margin of safety over mechanical screening, often holding significant cash reserves while waiting for idiosyncratic opportunities.

The firm maintains a reputation for navigating complex credit cycles and distressed debt situations. Klarman's recent commentary in June 2026 suggests he views the current market as having bubble-like characteristics driven by AI optimism.

New buys

Baupost's latest 13F filing shows a clear preference for established, cash-generative businesses alongside targeted biotech exposure. The firm is actively avoiding the AI-driven valuation premiums seen in the broader market.

These positions reflect a strategy focused on AI-agnostic opportunities. The firm continues to prioritize intrinsic value over momentum-based growth.

  • AON: 769,000 shares added as part of a broader high-conviction value strategy.
  • V: 701,355 shares purchased, consistent with a focus on high-quality, cash-generative business models.
  • TFX: 1,595,000 shares acquired in a move to increase exposure to medical technology.
  • NCLH: 3,630,000 shares added, reflecting a contrarian bet on the travel and leisure sector.
  • PCVX: 800,000 shares bought, representing a specific play in the biotechnology space.
New buys

What Seth Klarman sold

Baupost executed a clean sweep of its financial technology holdings during the second quarter of 2026. The firm exited three major positions entirely, likely to reallocate capital into its new high-conviction targets.

The divestments suggest a rotation out of legacy financial services infrastructure providers. This move aligns with Klarman's stated caution regarding current market valuations.

  • FIS: Sold 100% of the position, marking a complete exit from the firm.
  • DG: Sold 100% of the position, removing the discount retailer from the portfolio.
  • FISV: Sold 100% of the position, liquidating the remaining stake in the financial technology provider.

Read-through for retail

Retail investors should note that Klarman's portfolio changes are rarely driven by short-term sentiment. His focus remains on distressed credit and idiosyncratic situations, which are often inaccessible to individual market participants.

The shift toward V and AON suggests a preference for companies with strong competitive moats and pricing power. These businesses are less reliant on the speculative AI growth narrative that Klarman has publicly criticized.

  • Investors should monitor V for potential margin expansion as it remains a core focus for Baupost.
  • The exit from FIS and FISV indicates a potential cooling of sentiment toward traditional financial technology infrastructure.
  • PCVX offers a high-risk, high-reward profile that contrasts with the stability of the firm's other new holdings.
  • NCLH serves as a barometer for the health of the consumer discretionary sector in a high-interest-rate environment.
What to watch: The next major catalyst for the portfolio will be the Q3 2026 13F filing due in mid-November 2026.
Want this analysis on every stock you own?
Fintwit gives you AI stock analysis, real-time signals from X, and curated picks — built on the same data this post is grounded in.
Start Free Trial
Free to start. Premium just $9.99/mo — half the price of other research tools.